Deferasirox PCD Pharma Franchise Company
Cafoli Lifecare is a trusted Deferasirox PCD pharma franchise company in India, offering a focused range of 4 Deferasirox formulations manufactured at WHO-GMP certified facilities. We supply consistent, DCGI-approved iron chelator products to franchise partners and distributors who need dependable stock and district-wise monopoly support.
What is Deferasirox?
Deferasirox is an oral iron chelating agent that binds excess iron so it can be removed from the body. It is used to treat chronic iron overload caused by repeated blood transfusions. Learn more from the PubChem compound record.
Available Deferasirox Formulations
Our current Deferasirox portfolio spans 4 Deferasirox formulations available in the following forms: Tablets. Every batch is quality tested and released under WHO-GMP controls to ensure uniform quality across supply cycles.
Therapeutic Applications
Deferasirox is indicated for chronic iron overload in transfusion-dependent conditions such as thalassaemia. It is prescribed by haematologists and is dispensed strictly on prescription under qualified medical supervision.
Why Deferasirox is a High-Potential Molecule for Distributors
India has a large transfusion-dependent thalassaemia population, and an oral iron chelator like deferasirox meets a specialised, ongoing haematology requirement.
Why Choose Cafoli Lifecare
Partners receive district-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs, and the backing of a network of 1000+ franchise partners across India. Our supply reliability and compliance-first approach help you build a durable Deferasirox franchise business.
References
- PubChem: Deferasirox
- MedlinePlus: Deferasirox
- PubMed: Deferasirox research
Our formulations of Deferasirox find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: